CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease

Journal of Neuroimmune Pharmacology

Volumn 2, Issue 3, 2007, Pages 259-264

  Wang, Xi Jin ^a   Ye, Min ^a   Zhang, Yu Hong ^a   Chen, Sheng Di ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD200 CD200R; Microglia activation; Parkinson's disease

Indexed keywords

ANTIGENS, CD200; CD200R1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; HUMAN; METABOLISM; MICROGLIA; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; HUMANS; MICROGLIA; PARKINSON DISEASE; RECEPTORS, CELL SURFACE;

EID: 34547681540     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-007-9075-1     Document Type: Article

References (60)

1. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, Stewart CA, Kim HC, Bing G (2006) Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging (in press)
2. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003) A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 23:2665-2674
3. Banerjee D, Dick AD (2004) Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. Ocul Immunol Inflamm 12:115-125
4. Barclay AN (1981) Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens. Immunology 44:727-736
5. Barclay AN, Ward HA (1982) Purification and chemical characterisation of membrane glycoproteins from rat thymocytes and brain, recognised by monoclonal antibody MRC OX 2. Eur J Biochem 129:447-458
6. Bartolome MV, Ibanez-Olias MA, Gil-Loyzaga P (2002) Transitional expression of OX-2 and GAP-43 glycoproteins in developing rat cochlear nerve fibers. Histol Histopathol 17:83-95
7. Basu A, Krady JK, Enterline JR, Levison SW (2002) Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized. Glia 40:109-120
8. Berman ME, Muller WA (1995) Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 154:299-307
9. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77-98
10. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD (2002) Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 161:1669-1677
11. Bukovsky A, Presl J, Zidovsky J, Mancal P (1983) The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube. Immunology 48:587-596
12. Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Siklos L, Appel SH (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55:1075-1080
13. Deckert M, Sedgwick JD, Fischer E, Schluter D (2006) Regulation of microglial cell responses in murine toxoplasma encephalitis by CD200/CD200 receptor interaction. Acta Neuropathol (Berl) 111:548-558
14. Delgado M, Ganea D (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17:944-946
15. Di Monte DA (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2:531-538
16. Frank MG, Barrientos RM, Biedenkapp JC, Rudy JW, Watkins LR, Maier SF (2006) mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging 27:717-722
17. Gao HM, Hong JS, Zhang W, Liu B (2002a) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782-790
18. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002b) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297
19. Gao HM, Hong JS, Zhang W, Liu B (2003a) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23:1228-1236
20. Gao HM, Liu B, Zhang W, Hong JS (2003b) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 17:1957-1959
21. Gao HM, Liu B, Zhang W, Hong JS (2003c) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 17:1954-1956
22. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with ((11)C)(R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412
23. Gorczynski RM, Chen Z, Clark DA, Kai Y, Lee L, Nachman J, Wong S, Marsden P (2004a) Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 52:147-163
24. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA (2004b) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172:7744-7749
25. Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 6:483-488
26. Hatherley D, Barclay AN (2004) The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains. Eur J Immunol 34:1688-1694
27. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193
28. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768-1771
29. Ilan N, Madri JA (2003) PECAM-1: old friend, new partners. Curr Opin Cell Biol 15:515-524
30. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD (2006) Regulation of myeloid cell function through the CD200 receptor. J Immunol 176:191-199
31. Jones LL, Kreutzberg GW, Raivich G (1998) Transforming growth factor beta's 1, 2 and 3 inhibit proliferation of ramified microglia on an astrocyte monolayer. Brain Res 795:301-306
32. Kim YS, Joh TH (2004) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333-347
33. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309-6316
34. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151-170
35. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 21:8447-8855
36. Li R, Huang YG, Fang D, Le WD (2004) (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res 78:723-731
37. Liu B, Du L, Hong JS (2000a) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293:607-617
38. Liu B, Jiang JW, Wilson B, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS (2000b) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 295:125-132
39. Liu B, Gao HM, Hong JS (2003a) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065-1073
40. Liu B, Hong JS (2003b) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1-7
41. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS (2003c) Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305:212-218
42. Lu X, Bing G, Hagg T (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285-291
43. Morris RJ, Beech JN (1987) Sequential expression of OX2 and Thy-1 glycoproteins on the neuronal surface during development. An immunohistochemical study of rat cerebellum. Dev Neurosci 9:33-44
44. Nathan C, Muller WA (2001) Putting the brakes on innate immunity: a regulatory role for CD200? Nat Immunol 2:17-19
45. Newman PJ (1997) The biology of PECAM-1. J Clin Invest 99:3-8
46. Orth M, Tabrizi SJ (2003) Models of Parkinson's disease. Mov Disord 18:729-737
47. Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte DA (2007) Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 25:392-400
48. Qian L, Block ML, Wei SJ, Lin CF, Reece J, Pang H, Wilson B, Hong JS, Flood PM (2006) Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 319:44-52
49. Siglienti I, Chan A, Kleinschnitz C, Jander S, Toyka KV, Gold R, Stoll G (2007) Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions. J Neuropathol Exp Neurol 66:47-56
50. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964:288-294
51. Vieites JM, de la Torre R, Ortega MA, Montero T, Peco JM, Sanchez-Pozo A, Gil A, Suarez A (2003) Characterization of human cd200 glycoprotein receptor gene located on chromosome 3q12-13. Gene 311:99-104
52. Wang XJ, Chen SD, Ma GZ, Ye M, Lu GX (2005a) Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16:267-270
53. Wang XJ, Chen SD, Ma GZ, Ye M, Lu GZ (2005b) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 126:1241-1254
54. Wang XJ, Yan ZQ, Lu GQ, Stuart S, Chen SD (2007) Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: role of microglia. Neurochem Int 50:39-50
55. Webb M, Barclay AN (1984) Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones. J Neurochem 43:1061-1067
56. Wojtera M, Sikorska B, Sobow T, Liberski PP (2005) Microglial cells in neurodegenerative disorders. Folia Neuropathol 43:311-321
57. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13:233-242
58. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN (2001) The unusual distribution of the rat lymphoid/neuronal OX2 glycoprotein is conserved in humans (CD200). Immunology 102:173-179
59. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Edgwick JD, Phillips JH, Barclay AN (2003) Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171:3034-3046
60. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH (2004) Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173:6786-6793